TMCnet News
Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-OncologyCAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Tuesday, October 2, 2018, at 9:00 a.m. ET. A live audio webcast will be available within the Investor and News section of the Rubius Therapeutics’ website. An archived replay will be accessible for 90 days following the event. About Rubius Therapeutics Media Contact: Dan Budwick 1AB, Inc. +1 (973) 271-6085 [email protected] Investor Contact: |